Engineered PLGA microparticles for long-term, pulsatile release of STING agonist for cancer immunotherapy.

ABSTRACT: Activation of the stimulator of interferon gene (STING) pathway within the tumor microenvironment has been shown to generate a strong antitumor response. Although local administration of STING agonists has promise for cancer immunotherapy, the dosing regimen needed to achieve efficacy requires frequent intratumoral injections over months. Frequent dosing for cancer treatment is associated with poor patient adherence, with as high as 48% of patients failing to comply. Multiple intratumoral injections also disrupt the tumor microenvironment and vascular networks and therefore increase the risk of metastasis. Here, we developed microfabricated polylactic-co-glycolic acid (PLGA) particles that remain at the site of injection and release encapsulated STING agonist as a programmable seque

SUBMITTER: Lu X 

PROVIDER: S-EPMC9019818 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature